SD HEALTHCARE
Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Dexcom Delivers With Impressive Q3 Results
Company Looking At Various Avenues to Expand Its MarketIn what an analyst called another blowout quarter, Dexcom on Nov. 6 posted $396.3 million in third quarter revenue, a 49% year-over-year increase.Avidity Biosciences Raises $100M Round
Avidity Biosciences bagged a $100 million series C round to work on a pipeline of preclinical programs for muscle disorders and other diseases.
Spine Treatment Startup Carlsmed Names New COO
Carlsmed, a San Diego-based startup that uses predictive analytics to plan spine surgeries, named a new COO.
Grants Give Researchers Tools To Tackle Problems
Oceanographers Team Up to Examine Toxic Algae Blooms
Toxic algae blooms. Injuries from nerve damage. Brain disorders- these are problems San Diego researchers hope to better understand.
Merck Buys Calporta, Deal Worth up to $576M
In 2017, Merck & Co. cut short a late-stage clinical trial of an Alzheimer’s drug because it wasn’t helping patients, one of many failures that led big pharma to scale back efforts to try and treat brain disease.
After Valuation Plummet, Human Longevity Raises $30M
Human Longevity Inc. has raised $30 million, a year after a letter from the company’s board signaled a cash crunch at the genomics outfit.
LifeNet Health Acquires Organovo Subsidiary
LifeNet Health has acquired Samsara Sciences, a subsidiary of Organovo that provides human liver cells for drug research.
Currax Buys Nalpropion, Gains Weight-Loss Drug
New Jersey’s Currax Pharmaceuticals now holds the rights to contrave, a weight-loss drug with San Diego roots.
After Missing Mark in Clinical Trials, Halozyme Focuses on Delivery Platform
BIOTECH: Cancer Drug Failed to Extend Patient Lives
For many biotechs, the news would be a death knell.
The Ups and Downs Of Third Quarter Life Sciences Leasing
PROPERTY: Mirati Leads the 20 Deals Made With 64,108 Square Feet
More life sciences companies took space in the third quarter, but industry leasing activity still fell compared with the same period a year ago.
Neurocrine Reports 46% Spike in Revenue for Q3
PHARMA: Company Positioning Itself to Be a Leading Global Biopharma Organization
Neurocrine Biosciences reported revenue of $222.09 million in third quarter results.
Tandem Diabetes Care Reports Jump in Q3 Sales
Tandem Diabetes Care logged a jump in third quarter revenue as the company moved toward profitability.
Gut Health Is Goal Of Sun Genomics’ Custom Probiotics
Targeted Solutions Said To Take Complexity of Microbiome Into Account
A crop of companies take a person’s fecal sample and profile the microbiome, living microorganisms in the digestive system that are getting increased attention.
Heron Candidate Could Be Pain Med Alternative to Opioids
Analyst Sees Potential As Blockbuster Treating Postoperative Pain
In April, the U.S. Food and Drug Administration kicked back an application from Heron Therapeutics asking for approval of its experimental pain medicine.
Intrepida Bio Launches with $9.5M
Intrepida Bio seeks to modulate the immune system to fight cancer and other diseases.
Prev Next